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Background: To evaluate the expression and differential significance of c-Jun, p73, Casp-9 and N-ras in thymic
epithelial tumors (TETs) with the aim to provide useful information for tumor biology and prospective therapy.
Methods: In this study, we analyzed the expression of four chromosome 1-related genes, namely c-Jun, p73,
Casp-9 and N-ras, in 60 cases of thymic epithelial tumors. The tumors included 52 thymomas and 8 thymic
carcinomas which were categorized according to the current WHO classification systems.
Results: Compared with the normal thymus tissue, all thymic epithelial tumors demonstrated higher expression of
c-Jun and p73. The expression of c-Jun and p73 in type B2, B3 thymoma and thymic carcinomas was similar, and
significantly higher than that in all other subtypes of thymomas. Unlike type A thymoma, the expression of Casp-9
was relatively lower in type B thymoma and thymic carcinomas. With respect to the clinical staging systems, c-Jun
was more expressed in progressive tumors harboring higher stages. In contrast to c-Jun, p73 and Casp-9, there was
no significant aberration with N-ras expression irrespective of either tissue or tumor types.
Conclusions: The overexpression of c-Jun, p73 and Casp-9 in thymic epithelial tumors is closely related with the
pathogenesis and biological behavior of the neoplasms. These candidate biomarkers provided useful information
for prospective personalized therapy in the clinical management.
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Thymic epithelial tumors (TETs) are a panel of rare neo-
plasms, located in anterior mediastinum, accounting for
approximately 0.2-1.5% of all human malignancies [1].
TETs present with apparently distinctive histologic char-
acteristics from other malignancies, however, a big chal-
lenge for further subtype to many general pathologists in
the routine diagnosis [2]. Thymoma is one of the most
common subtypes of TETs and consists with a spectrum
of heterogeneous tumors presenting with thymic differ-
entiation but differ in morphology and clinical behavior
[3-5]. Based on the morphology, function and genetic
features, thymoma was re-categorized into type A, AB,
B1, B2, B3, and some other rare subtypes by World
Health Organization (WHO) in 2004 [6]. It has been
reported that type A and type AB thymoma employed
with benign biological behavior, whereas type B thym-
oma presented with pernicious characteristics to some
extent. Specifically, type B3 thymoma has a distinctively
poor prognosis compared with other subtypes [7-9].
TETs subtypes closely related to the therapeutic sche-
dules and prognosis of these diseases, however, reliable
and rational methods for recognizing these subtypes are
insufficient so far, if any.
Zettl et al.[10] declared that different TETs subtypes
shared various recurrent genetic aberrations, and gain of
chromosome 1 was the most common recurrent aberra-
tion (69%) in type B3 thymoma, which might be an at-
tractive landmark for the clinical diagnosis. And the
same results have been validated by the followed studies
[11,12]. Evidences indicated that genes located in
chromosome 1 were closely related to the initiation and
progression of several human malignancies, c-Jun (1p32-
31), p73 (1p36.3), Casp-9 (1p36.21), and N-ras (1p13.2)
were such kind of genes, which might involved in the
process of origination, proliferation, differentiation, and
apoptosis of the malignant cell [13-17]. However, few
studies were reported in TETs. Based on a clinicopatho-
logic analysis of 80 cases with immunohistochemical re-
action, Moran et al. indicated that the behavior of
primary thymic neuroendocrine carcinomas seems cor-
related with tumor differentiation [18]. Alexiev et al.
declared that autoimmune related disorders of thymoma
contained with a significant population of CD20+ intra-
tumoral B lymphocytes, and strong CD57 expresssion in
thymomas may indicated with a concomitant neuromus-
cular disorder [19]. Besides, It was reported that a com-
bined therapy may be considered as an another
promising option (e.g. COX-2 inhibitors plus anti-EGFR
antibody), especially when established chemotherapeutic
schemes did no work[20].
To our knowledge, the combination of expression of
c-Jun, p73, Casp-9, and N-ras was firstly evaluated in
different subtypes of thymic epithelium tumors andnormal thymus tissue. By trying to investigate the ex-
pression characteristics of those antibodies, we aim to
build an efficient panel of biomarkers for clinical differ-
ential diagnosing between subtypes of TETs.
Materials and methods
TETs cases included were formaldehyde-fixed, paraffin-
embedded (FFPE) archival samples from the Department
of Pathology in First Affiliated Hospital of Xinjiang Med-
ical University between January 2001 and February 2010.
All of the archival slides were reviewed by two inde-
pendent senior pathologists (YQM and QXL) according
to the latest WHO criteria, and any discrepancy between
these two investigators was resolved with a third re-
viewer (WZ) in order to reach an ultimate decision on
all of the items. Finally, 60 cases were recruited based on
the following criteria: 1) pathologically confirmed TETs
(thymoma and thymic carcinoma), 2) integrated clinico-
pathological information, 3) without any chemotherapy/
radiotherapy performed prior to recruitment. Among
those, including 26 male and 34 female (1:1.3) with an
average age of 48.5 years (range 25–73 years). In
addition, 11 normal biopsy thymic tissues were used as
normal control (provided by Teaching and Research
Office of Pathology, Basic Medical Academy of Xinjiang
Medical University). Informed consent was obtained
from all of the case and control subjects. All specimens
were handled and approved by the hospital’s ethics
committee.
Information of the total TETs was extracted based on
the criteria from the CAP website data (www.cap.org >
cancer protocols > thorax > thymoma and thymic car-
cinoma). Briefly, information of specimen integrity,
histologic subtypes, regional lymph nodes, tumor exten-
sion, and procedure treatment were obtained from the
surgical document, if any. Pathologic staging for thym-
omas according to Modified Masaoka Stage system;
and staging for thymic carcinomas according to pTNM
system [6].
Reagents and Immunohistochemistry
The antibodies included: c-Jun (mouse monoclonal anti-
human antibody sc-1694; 1:60; nucleus; Jingqiao Zhong
Shan Biotechnology, Beijing, China); p73 (mouse mono-
clonal anti-human antibody; 1:60; cytoplasm; Boshide
Biotechnology Wuhan, China); Casp-9 (mouse monoclo-
nal anti-human antibody MCH6; 1:60; cytoplasm;
Boshide Biotechnology Wuhan, China) and N-ras
(mouse monoclonal anti-human antibody; 1:100; cyto-
plasm; Boshide Biotechnology Wuhan, China).
Experimental procedures were performed as previously
described [21]. Briefly, serial 3-μm sections from formalin-
fixed, paraffin-embedded tissues were collected onto poly-
L-lysine coated slides and processed with a standard
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free detection system (Dakao, Colorado, USA) after a
heat-induced antigen retrieval procedure. Ready-to-use
Kit (EnVisionTM, Dakao, Colorado, USA) was used to
visualize tissue antigens according to manufacturer’s
instructions. Positive, Negative, and blank control was
routinely performed.
Immunohistochemical evaluation
Immunoreactivity was assessed by two senior pathologist
(YQM and XL) who were blinded to clinicopathologic
data, and any disagreements were resolved with a third
reviewer (WZ) using a multi-headed microscope. Scor-
ing of immunohistochemistry was based on two para-
meters: intensity of immunoreactivity and the exact
location of immunoreaction. The immunostaining inten-
sity was scored using the following semi-quantitative
scale: 1) -, no reactivity (no staining or weak staining less
than 5% of the target cells), 2) +, cases presented specific
staining of more than 5% of the target cells, regardless of
staining intensity, were scored as positive for c-Jun, p73,
Casp-9 or N-ras[22].
Statistical Analysis
Statistical analysis was performed using SPSS version
13.0. Group comparisons of categorical variables were
evaluated using the Fisher’s exact or Pearson’s chi-
square test. All P-values were two-sided, P-values less
than 0.05 were considered to be statistically significant,
less than 0.01 meant highly significant.
Results
Clinicopathologic results
Among the total 60 TETs, most of which involved an-
terior mediastinum (58/60), only one of these TETs
involved superior mediastinum and right mid-lower
mediastinum, respectively. The maximum diameters of
the samples in our study ranged from 1.8 to 14.0 cm
(average, 6.14 cm), among those, two type A, 19 type
AB, four B1, 14 B2, 11 B3, two metaplastic thymoma,
and eight thymic carcinoma were observed(seven pri-
mary squamous cell carcinomas, and one primary well-
differentiated neuroendocrine carcinoma). 21 TETs
cases employed an uninvolved-margin, as well as 39
margins involved by tumor. Concerning to the staging
information, among 52 thymomas, there were 21 stage
I, 19 stage II, 11 stage III, and one stage IV based on
the Modified Masaoka Stage system; among eight
thymic carcinomas, there were one T2N0M0, four
T3N0M0, two T4N0M0 and one T4N1M0 based on the
pTNM system; however, in order to obtained a powerful
statistic results, we transform pTNM of thymic carcin-
oma into Mosaoka tumor stages based on comparison
of Masaoka tumour stages and corresponding TNMclassification [6], and the final results were 21 stage I,
20 stage II, 15 stage III, four stage IV based on the
Modified Masaoka Stage system. No regional lymph
node metastasis was found excepted for only one
thymic carcinoma. No lymph-vascular invasion was
observed in the current study. Most of the patients (48/
60) saw a doctor due to chest pain and cough, in which
17 of the patients (28.3%) had myasthenia gravis (one of
type A, four of type AB, eight of type B2, and four of
Type B3). However, the remainder cases were asymp-
tomatic and found by routine physical examination. Fol-
low up data were available for 14 patients only [14],
among which five of type AB, two of type B1, three of
B2, one of B3, one of metaplastic thymoma and two of
thymic carcinoma. Post-operative follow-up range from
two months to 84 months, during the follow-up period,
all cases were still alive, three cases (two of B2, one of
AB) recur ptosis after operation and radiotherapy.
Immunohistochemistry results
In order to evaluate the diagnostic significance of c-Jun,
p73, Casp-9, and N-ras expression in the distinction of
TETs, we detected these markers with immunohisto-
chemistry. The results of immunohistochemistry were
seen in Figure 1.
c-Jun expression: The expression of c-Jun was mainly
located in nucleus in the tumorous epithelium of thym-
oma. Statistically, it was found that expression of c-Jun
in TETs was significantly higher than that in normal thy-
mus tissue (P < 0.05, Table 1). Furthermore, statistical
significant differences of c-Jun expression between sub-
types were observed (P < 0.05), either. Thymic carcin-
oma , Type B3 and Type B2 thymoma ranked the first
higher expression rate of c-Jun; they were 87.5% (7/8),
45.5% (5/11), and 42.9% (6/14), respectively. However,
immunoreactions were not seen in Type A, B1, and
metaplastic thymoma (Table 1). A statistical significant
result between c-Jun expression and various clinical
stages of TETs were found (P < 0.05), c-Jun expression
were definitely higher in high stage (III + IV) when com-
pared with the low stage (I + II) TETs (P < 0.01). How-
ever, no statistical discrepancy was observed in stage I
vs. II, as well as stage III vs. IV, respectively (P > 0.05)
(Table 2).
Caspase-9 expression: Similar Caspase-9 expression
was observed both in thymic epithelium tumors and
normal tissue, no statistics difference between them was
observed (P > 0.05, Table 1). And significant difference
of Caspase-9 expression among different subtypes of
thymic epithelium tumors (P < 0.05) was observed, as
showed in Table 1, almost all of the type A and meta-
plastic thymoma expressed Caspase-9 antibody, whereas
none of the type B1 thymoma positive expression was
observed. What’s more, an increasing immunoreactivity
A: 
J: I: H:G:F:




Figure 1 c-Jun, N-ras, Caspase-9 and p73 immunoreactivity in TETs. A-C: c-Jun staining in typeAB, B3 and thymic carcinoma; D,E: N-ras
staining in typeA and B3; F,G: Caspase-9 staining in typeB2 and B3; H-J: p73 staining in typeA, AB and B2. EnVision, Scale bar: 50 μm Olympus
CX51. photoshop software (PS).
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were 38.1% (Stage I), 55.0% (Stage II), 53.3% (Stage III),
and 75.0% (Stage IV), respectively, however, no statisti-
cally discrepancy was observed between stages (P > 0.05,
Table 2).
P73 expression: Over-expression of p73 in thymic epi-
thelium tumors was observed, and presented signifi-
cantly discrepancy when compared with normal tissue
(P < 0.05), as well as compared among subtypes (P <
0.05). The respective expression of p73 in type B3, type
B2 and type B1 were 72.2% (8/11), 64.3% (9/14), and 0%
(0/4), as showed in Table 1. It was indicated that type B3
has a significantly high expression of p73 than non-type
B3 thymomas (P < 0.05). Meanwhile, there was no sig-
nificant difference of p73 expression between type B3,
B2 thymoma and thymic carcinoma (P>0.05, data not
shown). p73 positive expression in different clinical
stages of thymoma was 38.1% (Stage I), 55.0% (Stage II),
53.3% (Stage III), and 75.0% (Stage IV), respectively. No
statically significant among different clinical stages of
p73 expression was observed (P > 0.05, Table 2).Table 1 Distribution of c-Jun, N-ras, Caspase9 and p73 expres
(TETs) n (%)
Type-A Type-AB Type-B1 Type-B2 Type-B3
N=2 N=19 N=4 N=14 N=11
C-Jun 0 (0.0) 4 (21.0) 0 (0.0) 6 (42.9) 5 (45.5)
N-ras 1 (50.0) 3 (15.8) 0 (0.0) 1 (7.1) 5 (45.4)
Caspase9 2 (100.0) 5 (26.3) 0 (0.0) 10 (71.4) 7 (63.6)
p73 1 (50.0) 5 (35.7) 0 (0.0) 9 (64.3) 8 (81.8)
Tcaa: thymic carcinoma.
MTb: metaplastic thymoma.
NTc: normal thymic tissue.
Pd: Two-sided Fisher’s exact test for distributions between different histologic subty
Pe: Two-sided Fisher’s exact test for distributions between cases and controls.
Pf: Two-sided Pearson’s chi square test for distributions between lower-grade TETs (N-ras expression: There was no significant difference
of N-ras expression between thymic epithelium tumors
and normal tissue controls (P > 0.05) (Table 1), similar
negative results were observed among different subtypes
of TETs (P > 0.05, Table 1). N-ras positive rates of differ-
ent clinical stages of thymic epithelium tumors were
14.3% (Stage I), 15.0% (Stage II), 40.0% (Stage III), and
0% (Stage IV), respectively, among which no significant
difference of N-ras expression was found (P > 0.05,
Table 2).
We also evaluated the expression distribution of
those four antibodies between low-grade TETs (in-
cluding type-A, type-AB, typeB1, and metaplastic
thymoma) and high-grade TETs (including type-B2,
type-B3, and thymic carcinoma), and found that c-
Jun, Caspase-9, and p73 expression was statistically
significant with high-grade TETs, the P-values were
0.002, 0.019, and 0.004, respectively. No statistically
significant discrepancy was found between the expres-
sion of those antibodies and some other clinicopatho-
logical characteristics.sion in different subtypes of thymic epithelial tumors
Tcaa MTb Total NTc Pd Pe Pf
N = 8 N=2 N=60 N=11
7 (87.5) 0 (0.0) 22 (36.7) 0 (0) 0.011 0.014 0.002
2 (25.0) 0 (0.0) 12 (20.0) 3 (27.3) 0.187 0.888 0.364
4 (50.0) 2(100.0) 30 (50.0) 7 (63.6) 0.016 0.780 0.019
4 (50.0) 1 (50.0) 28 (46.6) 1 (9.1) 0.044 0.046 0.004
pes of thymoma.
type-A, AB, B1,MT) and higher-grade TETs (type-B2, B3, Tca).
Table 2 Different expression of c-Jun, N-ras, Caspase9 and p73 in different clinical stages of thymoma n (%)
Stage I N= 21 Stage II N= 20 Stage III N = 15 Stage IV N=4 Total N= 60 Pa Pb Pc Pd
C-Jun + 6 (28.6) 4 (20.0) 8 (53.3) 4 (100.0) 22 (36.7) 0.009 0.004 0.523 0.245
N-ras + 3 (14.3) 3 (15.0) 6 (40.0) 0 (0) 12 (20.0) 0.184
Caspase9 + 8 (38.1) 11 (55.0) 8 (53.3) 3 (75.0) 30 (50.0) 0.482
p73 + 6 (28.6) 10 (50.0) 9 (60.0) 3 (75.0) 28(46.6) 0.089
Pa: Two-sided Fisher’s exact test for distributions between different stages of TETs.
Pb: Two-sided Fisher’s exact test for distributions between stage III + IV and stage I + II of TETs.
Pc: Two-sided Fisher’s exact test for distributions between stage I and stage II of TETs.
Pd: Two-sided Fisher’s exact test for distributions between stage III and stage IV of TETs.
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Thymomas were neoplasms arising from or exhibiting
differentiation toward thymic epithelial cells. It has been
reported that different subtypes of thymoma have differ-
ent genetic characteristics, recent studies indicated that
chromosomal 1 gain plays an important role in molecu-
lar genetic mechanism of thymic epithelium tumors
[10,23-25].
C-Jun (cellular Jun), a member of nucleus transcrip-
tion factor, is an oncogene locating on chromosome 1. It
was indicated that the expression of c-Jun immunohisto-
chemistry can reveal the mRNA level of c-Jun [23]. In
this project, expression of c-Jun in 22 from 60 (36.7%)
TETs were observed, which specifically located on cell
nucleus. Statistical test showed that the abnormal ex-
pression of c-Jun was significantly higher in thymic epi-
thelium tumors than that in normal tissue controls.
There were also statistical differences of c-Jun positive
expression in different subtypes of thymoma. Among
those TETs, including thymic carcinomas, type B3, and
type B2 thymomas took the higher percentage immune
reaction (more than 40%) of c-Jun. Our results were
consistent with Sasaki’s research [23], indicating a strong
positive expression of c-Jun might correlate with high
grade TETs. Therefore, we speculated that c-Jun might
be regard as a potential positive regulator of cell
reproduction [26,27], or might play an important role in
the process of tumor differentiation. Besides, prolifera-
tion index Ki-67 was increase in type B3 thymoma cells
[28]. In our project, there were statistical differences of
c-Jun expression in different clinical stages of thymic
epithelium tumors: advanced thymomas (III + IV) were
significantly higher than those of the early thymomas
(I + II); and there was no statistical difference between
stage I and II; neither between stage III and stage IV.
This research showed that the expression of c-Jun
increased in invasive thymic tumors, which also sug-
gested that c-Jun might be used to help judging the bio-
logical behaviors, clinical stage, and prognosis of tumors.
N-ras is one of the ras gene family members locating
on chromosome 1. N-ras function as an important factor
in the process of cell proliferation, senescence,
immortalization and carcinogenesis. N-ras can alsoinhibit the cancer cells proliferation by Suv39h1 and
H3K9 methylation. Mutational ras protein can affect cell
proliferation, cell cycle regulation and anti-apoptotic sig-
nal by decreasing the activity of endogenous GTPase, or
transcriptional decreasing the expression of Fas receptor
and regulating the last time of the p38 activity of Jun N-
terminal protein kinase (JNK) by Ral-GEF (Ras related
GTPase-guanine exchange factor) pathway [29] Mean-
while, N-ras has different function to the generation of
cancer in different individuals[30-32]. In our study, N-
ras expression was found in 12 cases of TETs, however,
no significant difference was observed between thymic
epithelium and normal tissue controls, similar results
existed between the subtypes of thymic epithelium
tumors. The results suggested that N-ras might play a
role in the generation of thymic epithelium tumors.
However, it will be hard to indicate the relationship of
N-ras expression in different subtypes of thymic epithe-
lium tumors due to the small sample size of the current
study. Further studies are needed to confirm these
observations and to determine the mechanism of N-ras
in the origin and development of TETs. No statistical
differences were detected in N-ras expression of differ-
ent clinical stages of thymic epithelium tumors.
Caspase-9 gene locates on 1p36.3-p36.1. It precipitates
in mitochondria induced cell senescence pathway [32].
Several studies indicated that decreasing Caspase-9 tran-
scription and translation are detected in head and neck
squamous cell carcinoma [33], and leukemia [34]. In our
project, 30 out of 60 (50%) thymic epithelial neoplasms
have positive Caspase-9 expression, which was slightly
lower than the Caspase-9 expression in normal control
tissues (7/11, 63.6%). But the difference was not statisti-
cally significant. The result indicated that there were sig-
nificant differences among Caspase-9 over expressions
in different subtypes of thymic epithelium tumors. In
different subtype, the expression of Caspase-9 in thymic
epithelium tumors mainly existed in thymomas con-
structed by bland epithelial cells, including type A and
metaplastic thymoma. Caspase-9 presented a lower ex-
pression in type B thymoma and thymic carcinoma than
in type A and metaplastic thymoma, which was consist-
ent with previous research [33,34]. The decreasing
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cated that the interruption of Caspase-9 related apop-
tosis signaling pathways might promote the generation
of type B thymoma and thymic carcinoma. However, in
the current study, we first divided TETs into two groups
as described above (low-grade TETs and high-grade
TETs), and found that Caspase-9 presented relatively
lower expression in low-grade TETs when compared
with that in high-grade TETs. The mechanism was not
clear, and need more future studies to validate our
results. No statistical differences are detected in
Caspase-9 expression of different clinical stages of
thymic epithelium tumors.
p73 gene locates on human chromosome 1p36.33.
Many isomers of p73 were identified, and the expression
and interaction of those different isomers involved the
process of regulate transcription and growth inhibition
[35,36]. The fact that p73 abnormal expression was
observed more common in cancer tissues than in nor-
mal tissue indicated that p73 might be an oncogene [37].
In this project, over-expression of p73 in thymic epithe-
lium tumors was significantly higher than that in normal
control tissue. This result suggested that the expression
of p73 increased in thymic epithelium neoplasm, which
was similar with the previous research on digestive sys-
tem tumor [35]. The p73 protein detected by immuno-
histochemical methods were probably wild type. The
positive expression of p73 in different subtypes of
thymic epithelium tumors existed statistical differences.
In addition, our results indicated that p73 presented
with similar positive expression levels in type B2, B3
thymoma and thymic carcinoma, which were signifi-
cantly higher than other subtypes of thymoma. This con-
clusion suggested that p73 might play an important role
in type B2, B3 thymoma and thymic carcinoma. It was
also revealed that the molecular change of type B2, B3
thymoma might be similar with thymic carcinoma, and
differ from other types of thymoma. Considering previ-
ous research results of our group that p53 protein posi-
tive expression increased in type B3 thymoma [28], it
can be inferred that p73 and p53 protein mutants might
embrace a synergistic effect in thymoma. However, the
limitation of the follow-up data was too small to make
such conclusion, the further analysis between p73 ex-
pression and prognosis need more data from the future
follow-up data.
In summary, the results indicated that c-Jun and p73
expressed significantly higher in thymic epithelium
tumors than in normal control tissues. c-Jun and p73
also had similar positive expression level in high-grade
TETs, which is significantly higher than low-grade TETs.
In addition, Caspase-9 expression was relative lower in
type B thymoma and thymic carcinoma. However, no sig-
nificant difference of N-ras expression among differenttissues of the thymus and different thymic epithelium
tumors was observed. What we observed suggested that
different genes on chromosome 1 might employ different
functions in the generation and development of thymic
epithelium tumors. c-Jun and p73 may promote the
tumor formation. Previous studies of our group also sug-
gested that chromosome 1 gain was significantly higher
in thymic epithelium tumors than normal thymus tissue,
and it was also higher in type B3 thymic epithelium
tumors than other subtypes of thymoma [11]. It is highly
possible that type B3 thymoma has a different molecular
change with other types of thymoma, and similar with
thymic carcinoma. Those evidences suggested that type
B3 thymoma should be distinguished from other sub-
types of thymoma and might be classified as a intermedi-
ate malignant tumor, which needs more future studies to
validate our results before they can have widespread ap-
plication. Meanwhile, The use of a combination of c-Jun,
p73 and Caspase-9 could help differential diagnosing.
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